BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11054442)

  • 1. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.
    Fleischhack G; Hartmann C; Simon A; Wulff B; Havers W; Marklein G; Hasan C; Bode U
    J Antimicrob Chemother; 2001 Jun; 47(6):841-53. PubMed ID: 11389117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen.
    J Antimicrob Chemother; 1995 Jul; 36(1):185-200. PubMed ID: 8537265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
    Vandercam B; Gérain J; Humblet Y; Ferrant A; Wauters G; Moreau M; Longueville J; Symann M; Straetmans N
    Ann Hematol; 2000 Mar; 79(3):152-7. PubMed ID: 10803938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer.
    Chandrasekar PH; Arnow PM
    Ann Pharmacother; 2000 Sep; 34(9):989-95. PubMed ID: 10981242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
    Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
    Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
    Malik I; Shaharyar
    J Pak Med Assoc; 2002 Jan; 52(1):15-8. PubMed ID: 11963577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
    Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
    Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
    Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
    Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
    Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
    Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
    Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
    Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer.
    Chuang YY; Hung IJ; Yang CP; Jaing TH; Lin TY; Huang YC
    Pediatr Infect Dis J; 2002 Mar; 21(3):203-9. PubMed ID: 12005083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A; Bucaneve G; Menichetti F
    Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
    Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
    Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.